Aviado · Research
Longevity Daily
Tuesday, October 13, 2026
Listen
Today's Brief
GLP-1 drugs are no longer just a weight-loss story — Novo Nordisk and Eli Lilly's clinical data now show they measurably reduce biological age in patients, potentially reframing Ozempic as an anti-aging medicine. Researchers also reprogrammed blood cells from 80-year-olds into neural stem cells decades younger, while new AMPK findings give fresh credibility to one of aging biology's most promising targets. Today's Aviado deep dive explains Vitamin B6's conversion to PLP and its role in 150+ enzymatic reactions, while a KFF Health News investigation exposes real harms from unregulated peptides circulating in wellness culture.
10 stories4 peer-reviewed1 trials1 Aviado original
Cognitive Health & Neuroprotection
Scientists Rewound 80-Year-Old Blood Cells Into Neural Stem Cells Decades Younger
Researchers at the University of Bonn published a striking proof-of-concept in Aging Cell: blood-cell precursors from an 80-year-old donor were reprogrammed into neural stem cells with an epigenetic age below 20 — a reversal of more than six decades. The technique used just two transcription factors, SOX2 and cMYC, and took roughly 50 days, successfully resetting aging clocks in cells from donors as old as 101. If translatable to therapy, this kind of cellular rejuvenation could provide a pathway for treating age-related neurodegeneration using the patient's own cells.
Read more →Alzheimer's Brain Connectivity Changes Are Distinct From Normal Aging — And That Matters for Treatment
New research finds that patterns of functional brain connectivity in Alzheimer's disease differ meaningfully from those seen in typical aging — suggesting the disease isn't simply 'accelerated aging' but carries its own distinct neural signature. The finding has practical implications: if Alzheimer's-related changes are qualitatively different, not just quantitatively more severe, then treatments targeting generic brain aging may miss the mark entirely. Researchers note that distinguishing dysfunction from compensatory adaptation remains an open question — one that may only be resolved once effective therapies can be tested at scale.
Read more →Supplements & Compounds
How Vitamin B6 Becomes PLP — and Why That Conversion Is the Key to Its Benefits
Vitamin B6 only becomes biologically useful after converting to pyridoxal 5-phosphate (PLP), the active coenzyme form that powers 150+ enzymatic reactions — from making serotonin and GABA to processing homocysteine. Aviado Research's analysis finds the evidence is strongest for people with suboptimal B6 status or elevated metabolic demands, where raising PLP levels measurably shifts oxidative stress markers and cholesterol. For most, 10–50 mg/day of pyridoxine HCl normalizes PLP effectively, but the real benefit comes from identifying whether a specific PLP-dependent pathway is your personal bottleneck — something biomarker tracking can help clarify.
Read the full Aviado analysis →High-Dose Vitamin B6 Reduced Anxiety and Depression in Clinical Trial
A trial published in Human Psychopharmacology: Clinical and Experimental found that high-dose Vitamin B6 supplementation measurably reduced anxiety and depression symptoms, lending clinical weight to its known role in neurotransmitter synthesis. The mechanism runs through PLP: B6 must convert to its active coenzyme form before the brain can manufacture GABA (calming) and serotonin (mood-stabilizing). Today's Aviado deep dive explains exactly why that conversion step determines whether supplementation actually reaches those brain pathways.
Read more →Peptides Are Hurting People — and Under MAHA, Their Stories Are Being Suppressed
A KFF Health News investigation documents a pattern of adverse reactions to experimental peptides like BPC-157, which wellness influencers promote despite the complete absence of clinical trial data on human safety or efficacy. More troubling: under the current 'medical freedom' push, the regulatory infrastructure for collecting and acting on harm reports is being weakened rather than strengthened. If you're taking peptides based on social media recommendations, this reporting is essential reading — with no approved human trial data, every user is effectively an unmonitored test subject.
Read more →Research & Papers
GLP-1 Drugs Don't Just Cause Weight Loss — They Measurably Slow Biological Aging
For the first time at a major longevity conference, three pharmaceutical companies — including GLP-1 giants Novo Nordisk (Ozempic) and Eli Lilly (Mounjaro) — presented clinical trial results showing their drugs were associated with meaningfully lower biological age in patients compared to placebo. Overweight and diabetic patients on GLP-1 medications showed reductions in epigenetic aging markers independent of metabolic improvements, with independent analysis from third-party aging-clock companies adding credibility to the findings. This reframes GLP-1 medications as more than metabolic drugs — they may represent the first widely-prescribed medication class with clinically documented anti-aging effects in humans. Researchers caution the data are early and longer follow-up is essential, but the convergence of evidence from competing drug companies is striking.
Read more →Directly Activating AMPK Extended Lifespan Across Three Different Organisms
Researchers used a compound called 991 to directly activate AMPK — a cellular energy sensor that acts as a master regulator of metabolism — and found it extended lifespan across three model organisms. Unlike metformin, which activates AMPK indirectly while affecting other biological pathways, 991 allowed a cleaner test of whether AMPK itself is doing the longevity work. The results strengthen the scientific case that AMPK is a genuine anti-aging target and point toward next-generation compounds that could hit it more precisely than anything currently available.
Read more →Lifestyle & Nutrition
Longevity Experts Have a Message: Stop Believing These 6 Common Anti-Aging Claims
The New York Times gathered longevity researchers to push back on some of the most persistent anti-aging claims circulating online — including the idea that peptides, resveratrol, NAD+ boosters, or growth hormone can extend human lifespan. UC San Diego's Aladdin Shadyab was direct: no drug or supplement has been proven to extend the human lifespan, full stop, regardless of what influencers claim. It's useful calibration for anyone navigating the increasingly crowded space between credible longevity science and wellness marketing dressed up in the language of research.
Read more →Fasting for Autophagy? The Animal Evidence Is Strong — Human Evidence, Not So Much
A review in Biochemical Society Transactions draws a critical distinction that most wellness content ignores: while fasting robustly activates autophagy in animal models and is linked to improved lifespan, human data are far more limited and often methodologically weak. Most human studies measure steady-state autophagy gene expression — a poor proxy — rather than autophagic flux, the more rigorous readout of actual cellular turnover; where flux has been measured in humans, findings are frequently negative or inconclusive. If intermittent fasting is part of your longevity protocol specifically for autophagy benefits, this review suggests you may be running well ahead of the human evidence.
Read more →Industry & Policy
FDA and Industry Align on Priorities to Modernize Supplement Regulation
At CHPA's Regulatory, Scientific and Quality Conference, FDA officials and industry leaders converged on priorities for modernizing dietary supplement oversight — including standardizing quality requirements and deploying AI-based tools to identify illegal claims and unsafe products online faster. Kenvue's Greg Smith advocated for a phased approach rather than sweeping reform, noting that inconsistent standards across companies create an uneven playing field. The conversation is increasingly urgent: as today's KFF Health News investigation makes clear, the gap between what's on the market and what's been proven safe has real consequences for real people.
Read more →